Immuno-Oncology Research Applications

Great strides have been made in the field of cancer research as a result of harnessing native and modified cells of the immune system. Therapies using genetically modified T-cells have proven to be effective against certain hematologic malignancies. Antibodies that bind to checkpoint ligands and receptors have immensely increased the effectiveness of drug treatments and cell therapies against many types of cancers.

U-PLEX: MSD’s Most Flexible Assay Platform

The flexibility of the U-PLEX platform empowers you to make personalized multiplex assay combinations. Now you can build and run your multiplex assay at your convenience without any additional equipment or time-consuming assay development.

Discover new combinations with the quality and performance you expect from MSD.

 

U-PLEX Assay Designer
Use the U-PLEX Assay Designer to create custom panels from a selection of MSD assays, your own antibodies, or a combination of both.

U-PLEX Combinations for Immuno-Oncology Research

U-PLEX Combos represent popular combinations of assays, grouped into separate catalog numbers for ordering convenience.

Species	Name	Catalog Number	Assays
Human	CAR-T Cell Combo 1	K15338K NEW	GM‑CSF, Granzyme A, Granzyme B, IFN‑γ, IL‑2, TNF‑α
Human	Angiogenesis Combo 1	K15339K NEW	FGF (basic), PlGF, Tie‑2, VEGF‑A, VEGF‑D
Human	Target Cell Checkpoint Combo 1	K15340K NEW	CD276/B7‑H3, GITRL/TNFSF18, PD‑L1 (epitope 1), PD‑L2
Human	Effector Cell Checkpoint Combo 1	K15341K NEW	CD27, CD28, CD40L (soluble), CTLA‑4, GITR/TNFRSF18, HAVCR2/TIM‑3, LAG3, OX40/TNFRSF4, PD1 (epitope 1), TIGIT
Human	Immuno-Oncology Group 1 111-Plex	K15342K NEW	BAFF, BAFF‑R/TNFRSF13C, BDNF, BCMA/TNFRSF17, CD20, CD27, CD276/B7‑H3, CD28, CD40L (soluble), C‑Peptide, CTACK, CTLA‑4, ENA‑78, Eotaxin, Eotaxin‑2, Eotaxin‑3, EPO, FGF (basic), FGF‑23, FLT3L, Fractalkine, FSH, G‑CSF, Ghrelin (active), Ghrelin (total), GIP (active), GIP (inactive), GIP (total), GITR/TNFRSF18, GITRL/TNFSF18, GLP‑1 (active), GLP‑1 (inactive), GM‑CSF, gp130 (soluble), Granzyme A, Granzyme B, GRO‑α, HAVCR2/TIM‑3, I‑309, IFN‑α2a, IFN‑β, IFN‑γ, IL‑1α, IL‑1β, IL‑1RA, IL‑2, IL‑2Rα, IL‑3, IL‑4, IL‑5, IL‑6, IL‑7, IL‑8, IL‑9, IL‑10, IL‑12/IL‑23p40, IL‑12p70, IL‑13, IL‑15, IL‑16, IL‑17A, IL‑17A/F, IL‑17C, IL‑17D, IL‑17E/IL‑25, IL‑17F, IL‑18, IL‑21, IL‑22, IL‑23, IL‑27, IL‑29/IFN‑λ1, IL‑31, IL‑33, Insulin, IP‑10, I‑TAC, LAG3, Leptin, LH, MCP‑1, MCP‑2, MCP‑4, M‑CSF, MDC, MIF, MIP‑1α, MIP‑1β, MIP‑5, OX40/TNFRSF4, PD1 (epitope 1), PD1 (epitope 2), PD‑L1 (epitope 1), PD‑L2, PIGF, PP, Proinsulin, PYY (total), RANKL/TNFSF11, SDF‑1α, Tie‑2, TIGIT, TLR1, TNF‑α, TNF‑β, TPO, TRAIL, TSLP, VEGF‑A, VEGF‑D, YKL‑40

New Immuno-Oncology Assays

Individual assays can be configured into customized multiplex combinations of your choice.

Combine MSD assays with your own assays or with R-PLEX Antibody Sets for a truly custom multiplex.